Swiss privately-held AC Immune on Thursday said it has received an undisclosed milestone payment from the Swiss drug major Roche Group (VTX: ROG), which has now started a Phase III trial of AC Immune’s crenezumab to treat Alzheimer’s disease.
Chief executive of AC Immune, Andrea Pfeifer, said crenezumab has the potential to be one of the most promising therapies for this major global disease.
The Lausanne based company is engaged in the development of treatment for Alzheimer’s disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze